NICE decisions driven by cost-effectiveness, impacting access to healthcare treatments.
Cost-effectiveness is a major factor in NICE decisions, but not the only one. The study looked at NICE decisions up to 2011 and found that cost-effectiveness alone predicted 82% of decisions. Other factors like disease type also played a role. The model suggested that a technology costing £40,000 per quality-adjusted life-year had a 50% chance of NICE rejection. Past decisions seemed to use a higher threshold than the £20,000-£30,000/QALY range stated by NICE.